Edwards Lifesciences Corporation
Every calculator, already run for EW
Open the full toolkit →You have the numbers on EW. Get the argument.
A written report on which of these readings actually decide the outcome for Edwards Lifesciences Corporation, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
29 analysts covering EWAnalyst Price Target Disagreement for Edwards Lifesciences Corporation
Wall Street's bull case implies +27% from the current price; the bear case implies -3%. A 30% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for EW
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pr…
EW — frequently asked
Is EW a buy right now?
Wall Street's consensus rating on Edwards Lifesciences Corporation is Buy across 29 analysts, with a mean price target of $100.96 (+17% vs. the current $86.29). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is EW overvalued?
EW trades at 51.4x trailing earnings, against a DCF fair value of $48 per share. The current price implies 14% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is EW's next earnings date?
Edwards Lifesciences Corporation is next scheduled to report earnings around Oct 29, 2026. A full EW research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Edwards Lifesciences Corporation?
Analysts covering Edwards Lifesciences Corporation (EW) range from a bear-case target of $84.00 to a bull-case high of $110.00, with a mean consensus target of $100.96 across 26 analysts. The spread of $26.00 (30% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Edwards Lifesciences Corporation against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Edwards Lifesciences Corporation
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full EW research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Edwards Lifesciences Corporation, in minutes. 3 free reports included with every account — no credit card required.